{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T19:18:15Z","timestamp":1788376695738,"version":"build-2803163510"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9]]},"abstract":"Abstract<\/jats:title>\n \n Background:<\/jats:title>\n India has a significant burden of psoriasis, with an incidence reported between 0.44% and 2.2% among total dermatology patients and a reported prevalence of 4.78% over 5 years. Psoriasis is now recognized as a multisystem disease, and targeted therapies are needed to reduce morbidity. The need for newer biologics exists not only for better disease control but also to treat patients who manifest primary or secondary failure to a previous biologic. Ixekizumab is a newer IL-17 inhibitor that has recently been approved by the Drug Controller General of India for use in patients with psoriasis vulgaris in India.<\/jats:p>\n <\/jats:sec>\n \n Aims and Objectives:<\/jats:title>\n To evaluate the effectiveness and safety of ixekizumab in the treatment of patients with plaque psoriasis of Indian origin.<\/jats:p>\n <\/jats:sec>\n \n Patients and Methods:<\/jats:title>\n \n The study was a prospective, single-center, single-arm interventional study approved prospectively by Clinical Trial Registry-India with reg. no. CTRI\/2025\/02\/081205. The induction phase of ixekizumab was used to treat 40 patients with moderate-to-severe plaque psoriasis. The psoriasis area severity index (PASI), body surface area (BSA), and dermatology life quality index (DLQI) were measured at 2, 4, and 12 weeks of therapy. Median values of absolute PASI and BSA were assessed statistically using the Friedman test and Wilcoxon-signed rank test. PASI 75\/90\/100 responses were measured at 2, 4, and 12 weeks and analyzed using Cochran\u2019s\n Q<\/jats:italic>\n test and McNemar test. Safety and adverse events, if any, were documented.\n <\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n The median absolute PASI, BSA, and DLQI showed progressive improvement during the study period and these values when compared between baseline and 12 weeks were statistically significant. PASI 75\/90\/100 at the end of 12 weeks was 100%, 75%, and 20%, respectively. All eleven patients who had primary or secondary failure to a previous biologic showed a comparable response to that achieved by biologic na\u00efve patients. No major adverse events were noted.<\/jats:p>\n <\/jats:sec>\n \n Limitations:<\/jats:title>\n Considering that it is a pilot study which concluded in the induction phase of the treatment, long-term treatment outcomes and adverse events cannot be commented upon.<\/jats:p>\n <\/jats:sec>\n \n Conclusion:<\/jats:title>\n Ixekizumab achieved high PASI targets during the induction phase. The treatment improved the DLQI significantly. It has an excellent safety profile in the Indian population. Its effectiveness in patients with previous biologic failure is comparable to that in biologic na\u00efve patients.<\/jats:p>\n <\/jats:sec>","DOI":"10.4103\/idoj.idoj_1091_25","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T11:00:08Z","timestamp":1784631608000},"page":"648-653","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Effectiveness and Safety of Ixekizumab in Moderate-to-Severe Plaque Psoriasis in the Indian Population: A Pilot Study"],"prefix":"10.4103","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0847-8434","authenticated-orcid":false,"given":"Teghveer","family":"Singh","sequence":"first","affiliation":[{"name":"Department of Dermatology, Base Hospital Delhi Cantt and Army College of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shailendra","family":"Srivastava","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Base Hospital Delhi Cantt and Army College of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruby","family":"Venugopal","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Base Hospital Delhi Cantt and Army College of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reetu","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Base Hospital Delhi Cantt and Army College of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eeshaan","family":"Ranjan","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Base Hospital Delhi Cantt and Army College of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Base Hospital Delhi Cantt and Army College of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"key":"R1-20260902","doi-asserted-by":"crossref","first-page":"595","DOI":"10.4103\/0378-6323.72443","article-title":"Psoriasis in India: Prevalence and pattern","volume":"76","author":"Dogra","year":"2010","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"R2-20260902","first-page":"39","article-title":"Biologic treatments of psoriasis: An update for the clinician","volume":"15","author":"Brownstone","year":"2021","journal-title":"Biologics"},{"key":"R3-20260902","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s40801-024-00439-w","article-title":"Six-month real-world study to assess the effectiveness of ixekizumab after switching from IL-23 inhibitors and other biologic therapies: The Corevitas Psoriasis Registry","volume":"11","author":"Lebwohl","year":"2024","journal-title":"Drugs Real World Outcomes"},{"key":"R4-20260902","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1080\/14712598.2020.1729736","article-title":"Ixekizumab for the treatment of psoriasis: Up-to-date","volume":"20","author":"Craig","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"R5-20260902","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1080\/14712598.2023.2193288","article-title":"Real-life experience with ixekizumab in plaque psoriasis: A multicenter, retrospective, 3-year study","volume":"23","author":"Caldarola","year":"2023","journal-title":"Expert Opin Biol Ther"},{"key":"R6-20260902","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.jaad.2020.11.022","article-title":"Long-term efficacy and safety of ixekizumab: A 5-year analysis of the UNCOVER-3 randomized controlled trial","volume":"85","author":"Blauvelt","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"R7-20260902","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1111\/jdv.19161","article-title":"Speed of clinical improvement in the real-world setting from patient-reported Psoriasis Symptoms and Signs Diary: Secondary outcomes from the Psoriasis Study of Health Outcomes through 12 weeks","volume":"37","author":"Reich","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R8-20260902","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s40257-017-0332-7","article-title":"Psoriasis in skin of color: Insights into the epidemiology, clinical presentation, genetics, quality-of-life impact, and treatment of psoriasis in non-white racial\/ethnic groups","volume":"19","author":"Kaufman","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"R9-20260902","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/bjd.15753","article-title":"A systematic review of pharmacogenetic studies on the response to biologics in patients with psoriasis","volume":"178","author":"van Vugt","year":"2018","journal-title":"Br J Dermatol"},{"key":"R10-20260902","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s13555-022-00693-2","article-title":"Biologic therapy for moderate to severe psoriasis: Real-world follow-up of patients who initiated biologic therapy at least 10 years ago","volume":"12","author":"Elberd\u00edn","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"key":"R11-20260902","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3109\/09546634.2014.933166","article-title":"Efficacy and safety of adalimumab in psoriatic patients previously treated with etanercept in a real-world setting","volume":"26","author":"Fonseca","year":"2015","journal-title":"J Dermatolog Treat"},{"key":"R12-20260902","doi-asserted-by":"crossref","first-page":"e15193","DOI":"10.1111\/dth.15193","article-title":"Absolute psoriasis area and severity index as a valuable marker to determine initial treatment response in psoriasis patients treated with guselkumab in routine clinical care","volume":"35","author":"Seidl","year":"2022","journal-title":"Dermatol Ther"},{"key":"R13-20260902","doi-asserted-by":"crossref","first-page":"AB30","DOI":"10.1016\/j.jaad.2017.04.136","article-title":"Absolute and relative psoriasis area and severity indices over 1 year of treatment with ixekizumab: A descriptive analysis in patients with moderate-to-severe plaque psoriasis","volume":"76","author":"Mrowietz","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"R14-20260902","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1111\/bjd.18851","article-title":"A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial","volume":"182","author":"Blauvelt","year":"2020","journal-title":"Br J Dermatol"},{"key":"R15-20260902","doi-asserted-by":"crossref","first-page":"6215","DOI":"10.1111\/jocd.15217","article-title":"Ixekizumab treatment in patients with moderate-to-severe plaque psoriasis in a real-world clinical setting","volume":"21","author":"Demirel \u00d6\u011f\u00fct","year":"2022","journal-title":"J Cosmet Dermatol"}],"container-title":["Indian Dermatology Online Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/idoj.idoj_1091_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T19:00:20Z","timestamp":1788375620000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/idoj.idoj_1091_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/idoj.idoj_1091_25","relation":{},"ISSN":["2229-5178","2249-5673"],"issn-type":[{"value":"2229-5178","type":"print"},{"value":"2249-5673","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,21]]},"assertion":[{"value":"2025-09-05","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-21","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}